Staar Surgical CO STAA
We take great care to ensure that the data presented and summarized in this overview for STAAR SURGICAL CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding STAA
View all-
Broadwood Capital Inc New York, NY10.8MShares$199 Million20.84% of portfolio
-
Black Rock Inc. New York, NY7.49MShares$137 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.86MShares$107 Million0.0% of portfolio
-
State Street Corp Boston, MA2.05MShares$37.6 Million0.0% of portfolio
-
Resona Asset Management Co.,Ltd. Koto Ku,Tokyo, M01.5MShares$27.5 Million0.22% of portfolio
-
Geode Capital Management, LLC Boston, MA1.17MShares$21.5 Million0.0% of portfolio
-
Baillie Gifford & CO1.15MShares$21.2 Million0.02% of portfolio
-
Armistice Capital, LLC New York, NY872KShares$16 Million0.3% of portfolio
-
Dimensional Fund Advisors LP Austin, TX853KShares$15.7 Million0.01% of portfolio
-
American Capital Management Inc New York, NY848KShares$15.6 Million0.77% of portfolio
Latest Institutional Activity in STAA
Top Purchases
Top Sells
About STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Insider Transactions at STAA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 10
2025
|
Patrick F. Williams Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,061
+7.79%
|
-
|
Mar 07
2025
|
Patrick F. Williams Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,689
+6.26%
|
-
|
Mar 05
2025
|
Stephen C Farrell President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+25.3%
|
$120,000
$6.95 P/Share
|
Mar 04
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Mar 04
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
27,953
+0.12%
|
$475,201
$17.32 P/Share
|
Mar 03
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Mar 03
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
249,503
+1.03%
|
$4,241,551
$17.0 P/Share
|
Feb 28
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Feb 28
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
154,942
+0.65%
|
$2,634,014
$17.72 P/Share
|
Feb 27
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Feb 27
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
259,316
+1.12%
|
$4,149,056
$16.98 P/Share
|
Feb 14
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Feb 14
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
36,532
+0.32%
|
$547,980
$15.49 P/Share
|
Feb 13
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Feb 13
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
115,282
+1.01%
|
$1,729,230
$15.84 P/Share
|
Feb 12
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Feb 12
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
259,616
+0.78%
|
$3,634,624
$14.89 P/Share
|
Jan 16
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Jan 16
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
8,221
+0.08%
|
$172,641
$21.5 P/Share
|
Jan 14
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 15.7K shares |
---|---|
Open market or private purchase | 1.22M shares |
Exercise of conversion of derivative security | 29.8K shares |
Payment of exercise price or tax liability | 14.9K shares |
---|